Abstract
Isavuconazonium sulfate (Cresemba—Astellas) has received FDA approval to treat invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). Aspergillosis and mucormycosis are fungal infections caused by the Aspergillus species and by the Mucorales order of fungi, respectively. Both infections are seen predominantly in immunocompromised patients and are life-threatening.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
